Valneva (NASDAQ:VALN) Stock Price Up 7.6% – What’s Next?

Valneva SE (NASDAQ:VALN) was up 7.6% on Thursday . The company traded as high as $7.24 and last traded at $7.18. Approximately 35,366 shares changed hands during trading, a decline of 34% from the average daily volume of 53,530 shares. The stock had previously closed at $6.67.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Valneva in a research note on Friday, January 31st.

Valneva Price Performance

The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The firm has a market cap of $561.51 million, a price-to-earnings ratio of -53.15 and a beta of 1.98. The stock has a 50-day moving average price of $4.46 and a 200 day moving average price of $5.65.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC increased its stake in shares of Valneva SE (NASDAQ:VALN) by 33.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 at the end of the most recent quarter. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.